High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-07

AUTHORS

K. Kanai, M. Kako, T. Kumada, H. Tsubouchi, T. Aikawa, M. Kojima, H. Harada, T. Kawasaki, M. Nakashima, H. Okamoto, S. Mishiro

ABSTRACT

Efficacy of standard regimens (e.g., 3–6 MU for 24 weeks) of alfa-IFN therapy for chronic hepatitis C has been limited, particularly in patients with HCV/1b. To see if higher-dose longer term treatment is more effective, we tried a 9 MU 60-week regimen. HCV/1b-infected chronic hepatitis patients received 9 MU IFNα2a everyday but Sunday for 2 weeks and thrice a week for next 10 weeks, and 76 patients became HCV RNA-negative while 81 remained positive. The RNA-negative patients were then randomized to receive 3 MU (group I, n=37) or 9 MU (group II, n=39) for 48 weeks. Of the RNA-positive patients, only those with normal ALT received another 9 MU 48-week treatment (group III, n=45). Sustained responders (SR) were defined as those with negative RNA and normal ALT 6 months after the therapy. SR rates based on intent-to-treat principle did not differ significantly between groups I and II (30% vs 41%), but those based on the protocol-compatible cases showed a significant difference (32% vs 56%, p=0.034). SR rate in group III was significantly lower than those in group II. Adverse effects of IFN, developed more frequently in groups II and III than in group I, were mostly reversible. In conclusion, our results encourage 9 MU 60-week IFNα treatment in HCV/1b-infected patients with careful attention to adverse effects, and suggest that the treatment should be discontinued if HCV RNA does not disappear within 12 weeks. More... »

PAGES

1545-1554

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s007050050397

DOI

http://dx.doi.org/10.1007/s007050050397

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034445880

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9739333


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon alpha-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417200.0", 
          "name": [
            "Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanai", 
        "givenName": "K.", 
        "id": "sg:person.01330017252.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330017252.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Fourth Department of Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital, Kanagawa, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.264706.1", 
          "name": [
            "The Fourth Department of Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital, Kanagawa, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kako", 
        "givenName": "M.", 
        "id": "sg:person.01022667506.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022667506.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416762.0", 
          "name": [
            "Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kumada", 
        "givenName": "T.", 
        "id": "sg:person.0770416306.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770416306.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Second Department of Medicine, Miyazaki Medical College, Miyazaki, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "The Second Department of Medicine, Miyazaki Medical College, Miyazaki, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsubouchi", 
        "givenName": "H.", 
        "id": "sg:person.01106573463.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106573463.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Aikawa Internal Hospital, Ibaraki, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medicine, Aikawa Internal Hospital, Ibaraki, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aikawa", 
        "givenName": "T.", 
        "id": "sg:person.01261704052.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261704052.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Kojima Internal Clinic, Gifu, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medicine, Kojima Internal Clinic, Gifu, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kojima", 
        "givenName": "M.", 
        "id": "sg:person.011276771725.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011276771725.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Tokyo National Chest Hospital, Tokyo, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417136.6", 
          "name": [
            "Department of Medicine, Tokyo National Chest Hospital, Tokyo, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harada", 
        "givenName": "H.", 
        "id": "sg:person.011764702202.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011764702202.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Second Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.505613.4", 
          "name": [
            "The Second Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawasaki", 
        "givenName": "T.", 
        "id": "sg:person.01001517660.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001517660.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.505613.4", 
          "name": [
            "Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakashima", 
        "givenName": "M.", 
        "id": "sg:person.016335167212.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016335167212.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology Division, Jichi Medical School, Tochigi, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410804.9", 
          "name": [
            "Immunology Division, Jichi Medical School, Tochigi, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okamoto", 
        "givenName": "H.", 
        "id": "sg:person.0674453736.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674453736.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417200.0", 
          "name": [
            "Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mishiro", 
        "givenName": "S.", 
        "id": "sg:person.011312000645.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011312000645.84"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-07", 
    "datePublishedReg": "1998-07-01", 
    "description": "Efficacy of standard regimens (e.g., 3\u20136 MU for 24 weeks) of alfa-IFN therapy for chronic hepatitis C has been limited, particularly in patients with HCV/1b. To see if higher-dose longer term treatment is more effective, we tried a 9 MU 60-week regimen. HCV/1b-infected chronic hepatitis patients received 9 MU IFN\u03b12a everyday but Sunday for 2 weeks and thrice a week for next 10 weeks, and 76 patients became HCV RNA-negative while 81 remained positive. The RNA-negative patients were then randomized to receive 3 MU (group I, n=37) or 9 MU (group II, n=39) for 48 weeks. Of the RNA-positive patients, only those with normal ALT received another 9 MU 48-week treatment (group III, n=45). Sustained responders (SR) were defined as those with negative RNA and normal ALT 6 months after the therapy. SR rates based on intent-to-treat principle did not differ significantly between groups I and II (30% vs 41%), but those based on the protocol-compatible cases showed a significant difference (32% vs 56%, p=0.034). SR rate in group III was significantly lower than those in group II. Adverse effects of IFN, developed more frequently in groups II and III than in group I, were mostly reversible. In conclusion, our results encourage 9 MU 60-week IFN\u03b1 treatment in HCV/1b-infected patients with careful attention to adverse effects, and suggest that the treatment should be discontinued if HCV RNA does not disappear within 12 weeks.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s007050050397", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1083335", 
        "issn": [
          "0304-8608", 
          "1432-8798"
        ], 
        "name": "Archives of Virology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "143"
      }
    ], 
    "keywords": [
      "chronic hepatitis patients", 
      "sustained responders", 
      "HCV RNA", 
      "hepatitis patients", 
      "group II", 
      "RNA-negative patients", 
      "alfa-interferon therapy", 
      "RNA-positive patients", 
      "group I", 
      "adverse effects", 
      "chronic hepatitis C", 
      "HCV genotype 1b", 
      "long term treatment", 
      "normal ALT", 
      "standard regimens", 
      "hepatitis C", 
      "treat principle", 
      "IFN\u03b1 treatment", 
      "genotype 1b", 
      "term treatment", 
      "patients", 
      "SR rates", 
      "group III", 
      "therapy", 
      "weeks", 
      "HCV/1b", 
      "negative RNA", 
      "significant differences", 
      "treatment", 
      "careful attention", 
      "regimens", 
      "regimen", 
      "IFN", 
      "ALT", 
      "responders", 
      "mu", 
      "RNA", 
      "months", 
      "efficacy", 
      "thrice", 
      "rate", 
      "conclusion", 
      "effect", 
      "differences", 
      "cases", 
      "intent", 
      "Sunday", 
      "results", 
      "attention", 
      "everyday", 
      "principles", 
      "alfa-IFN therapy", 
      "higher-dose longer term treatment", 
      "MU 60-week regimen", 
      "MU 48-week treatment", 
      "normal ALT 6 months", 
      "ALT 6 months", 
      "protocol-compatible cases", 
      "MU 60-week IFN\u03b1 treatment", 
      "HCV/1b-infected patients", 
      "High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy", 
      "long-term (60 weeks) alfa-interferon therapy"
    ], 
    "name": "High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b", 
    "pagination": "1545-1554", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034445880"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s007050050397"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9739333"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s007050050397", 
      "https://app.dimensions.ai/details/publication/pub.1034445880"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_270.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s007050050397"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s007050050397'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s007050050397'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s007050050397'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s007050050397'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      21 PREDICATES      96 URIs      88 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s007050050397 schema:about N4cb741e6327444cf9265055548c4f7f6
2 N4e41252bf14948b4b87a999b19c47082
3 N692ef0a9f9144c1181be22e830daf006
4 N91330cbbb10747af9545d6bca841ca7c
5 Na6fba8d42d604ef1b5d980e5ac97d964
6 Nbdbcbd3339844f14b5ebd71b4e79ed40
7 Nef9eeb05234d4cdb87cac294d428b138
8 anzsrc-for:11
9 anzsrc-for:1103
10 schema:author Neb69d3fb99e5473aa3606263618dde71
11 schema:datePublished 1998-07
12 schema:datePublishedReg 1998-07-01
13 schema:description Efficacy of standard regimens (e.g., 3–6 MU for 24 weeks) of alfa-IFN therapy for chronic hepatitis C has been limited, particularly in patients with HCV/1b. To see if higher-dose longer term treatment is more effective, we tried a 9 MU 60-week regimen. HCV/1b-infected chronic hepatitis patients received 9 MU IFNα2a everyday but Sunday for 2 weeks and thrice a week for next 10 weeks, and 76 patients became HCV RNA-negative while 81 remained positive. The RNA-negative patients were then randomized to receive 3 MU (group I, n=37) or 9 MU (group II, n=39) for 48 weeks. Of the RNA-positive patients, only those with normal ALT received another 9 MU 48-week treatment (group III, n=45). Sustained responders (SR) were defined as those with negative RNA and normal ALT 6 months after the therapy. SR rates based on intent-to-treat principle did not differ significantly between groups I and II (30% vs 41%), but those based on the protocol-compatible cases showed a significant difference (32% vs 56%, p=0.034). SR rate in group III was significantly lower than those in group II. Adverse effects of IFN, developed more frequently in groups II and III than in group I, were mostly reversible. In conclusion, our results encourage 9 MU 60-week IFNα treatment in HCV/1b-infected patients with careful attention to adverse effects, and suggest that the treatment should be discontinued if HCV RNA does not disappear within 12 weeks.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf N6ad0335ce5804bfea6dfa0688a693930
18 Nc8209de1d05249f09adc8bbbbc23b855
19 sg:journal.1083335
20 schema:keywords ALT
21 ALT 6 months
22 HCV RNA
23 HCV genotype 1b
24 HCV/1b
25 HCV/1b-infected patients
26 High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy
27 IFN
28 IFNα treatment
29 MU 48-week treatment
30 MU 60-week IFNα treatment
31 MU 60-week regimen
32 RNA
33 RNA-negative patients
34 RNA-positive patients
35 SR rates
36 Sunday
37 adverse effects
38 alfa-IFN therapy
39 alfa-interferon therapy
40 attention
41 careful attention
42 cases
43 chronic hepatitis C
44 chronic hepatitis patients
45 conclusion
46 differences
47 effect
48 efficacy
49 everyday
50 genotype 1b
51 group I
52 group II
53 group III
54 hepatitis C
55 hepatitis patients
56 higher-dose longer term treatment
57 intent
58 long term treatment
59 long-term (60 weeks) alfa-interferon therapy
60 months
61 mu
62 negative RNA
63 normal ALT
64 normal ALT 6 months
65 patients
66 principles
67 protocol-compatible cases
68 rate
69 regimen
70 regimens
71 responders
72 results
73 significant differences
74 standard regimens
75 sustained responders
76 term treatment
77 therapy
78 thrice
79 treat principle
80 treatment
81 weeks
82 schema:name High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b
83 schema:pagination 1545-1554
84 schema:productId N551a625ba0a840c69fff976f5abbf3fc
85 Nac9b5c0054a847c2a22c8f55756a2875
86 Nc74c5817205844af9b808bc7b7404912
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034445880
88 https://doi.org/10.1007/s007050050397
89 schema:sdDatePublished 2021-12-01T19:09
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher Nf4a36e3596b6443abc5a5442ef87a4b0
92 schema:url https://doi.org/10.1007/s007050050397
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N4cb741e6327444cf9265055548c4f7f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Recombinant Proteins
98 rdf:type schema:DefinedTerm
99 N4e41252bf14948b4b87a999b19c47082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Hepatitis C, Chronic
101 rdf:type schema:DefinedTerm
102 N551a625ba0a840c69fff976f5abbf3fc schema:name dimensions_id
103 schema:value pub.1034445880
104 rdf:type schema:PropertyValue
105 N692ef0a9f9144c1181be22e830daf006 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Humans
107 rdf:type schema:DefinedTerm
108 N6ad0335ce5804bfea6dfa0688a693930 schema:issueNumber 8
109 rdf:type schema:PublicationIssue
110 N84ffe8bb96e04a338e93922e77fd4855 rdf:first sg:person.01022667506.79
111 rdf:rest Nfdb4b3b9c6ee41678959127a73d7325f
112 N8863e6446c844754add32e5b4895fb65 rdf:first sg:person.011312000645.84
113 rdf:rest rdf:nil
114 N91330cbbb10747af9545d6bca841ca7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Genotype
116 rdf:type schema:DefinedTerm
117 N95490805aa3a4fb2a655274576f49fa9 rdf:first sg:person.01001517660.10
118 rdf:rest Ndd126a96b55942b099f0f0e47c9adcbd
119 Na1a71644b6bc4d049215f5141f2ffad7 rdf:first sg:person.01106573463.58
120 rdf:rest Ne7e339a38702474b9a54d21285f3a94c
121 Na3001a3e14fd4e4d83dc760971a854c4 rdf:first sg:person.0674453736.53
122 rdf:rest N8863e6446c844754add32e5b4895fb65
123 Na6fba8d42d604ef1b5d980e5ac97d964 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Hepacivirus
125 rdf:type schema:DefinedTerm
126 Nac9b5c0054a847c2a22c8f55756a2875 schema:name doi
127 schema:value 10.1007/s007050050397
128 rdf:type schema:PropertyValue
129 Nbdbcbd3339844f14b5ebd71b4e79ed40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Interferon alpha-2
131 rdf:type schema:DefinedTerm
132 Nc2b4d982fe9f465daf3b3370e605d3dd rdf:first sg:person.011276771725.14
133 rdf:rest Nef1bfa35f81845b09d0c7e54063ac654
134 Nc74c5817205844af9b808bc7b7404912 schema:name pubmed_id
135 schema:value 9739333
136 rdf:type schema:PropertyValue
137 Nc8209de1d05249f09adc8bbbbc23b855 schema:volumeNumber 143
138 rdf:type schema:PublicationVolume
139 Ndd126a96b55942b099f0f0e47c9adcbd rdf:first sg:person.016335167212.49
140 rdf:rest Na3001a3e14fd4e4d83dc760971a854c4
141 Ne7e339a38702474b9a54d21285f3a94c rdf:first sg:person.01261704052.37
142 rdf:rest Nc2b4d982fe9f465daf3b3370e605d3dd
143 Neb69d3fb99e5473aa3606263618dde71 rdf:first sg:person.01330017252.58
144 rdf:rest N84ffe8bb96e04a338e93922e77fd4855
145 Nef1bfa35f81845b09d0c7e54063ac654 rdf:first sg:person.011764702202.27
146 rdf:rest N95490805aa3a4fb2a655274576f49fa9
147 Nef9eeb05234d4cdb87cac294d428b138 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Interferon-alpha
149 rdf:type schema:DefinedTerm
150 Nf4a36e3596b6443abc5a5442ef87a4b0 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 Nfdb4b3b9c6ee41678959127a73d7325f rdf:first sg:person.0770416306.49
153 rdf:rest Na1a71644b6bc4d049215f5141f2ffad7
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
158 schema:name Clinical Sciences
159 rdf:type schema:DefinedTerm
160 sg:journal.1083335 schema:issn 0304-8608
161 1432-8798
162 schema:name Archives of Virology
163 schema:publisher Springer Nature
164 rdf:type schema:Periodical
165 sg:person.01001517660.10 schema:affiliation grid-institutes:grid.505613.4
166 schema:familyName Kawasaki
167 schema:givenName T.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001517660.10
169 rdf:type schema:Person
170 sg:person.01022667506.79 schema:affiliation grid-institutes:grid.264706.1
171 schema:familyName Kako
172 schema:givenName M.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022667506.79
174 rdf:type schema:Person
175 sg:person.01106573463.58 schema:affiliation grid-institutes:grid.410849.0
176 schema:familyName Tsubouchi
177 schema:givenName H.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106573463.58
179 rdf:type schema:Person
180 sg:person.011276771725.14 schema:affiliation grid-institutes:None
181 schema:familyName Kojima
182 schema:givenName M.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011276771725.14
184 rdf:type schema:Person
185 sg:person.011312000645.84 schema:affiliation grid-institutes:grid.417200.0
186 schema:familyName Mishiro
187 schema:givenName S.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011312000645.84
189 rdf:type schema:Person
190 sg:person.011764702202.27 schema:affiliation grid-institutes:grid.417136.6
191 schema:familyName Harada
192 schema:givenName H.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011764702202.27
194 rdf:type schema:Person
195 sg:person.01261704052.37 schema:affiliation grid-institutes:None
196 schema:familyName Aikawa
197 schema:givenName T.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261704052.37
199 rdf:type schema:Person
200 sg:person.01330017252.58 schema:affiliation grid-institutes:grid.417200.0
201 schema:familyName Kanai
202 schema:givenName K.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330017252.58
204 rdf:type schema:Person
205 sg:person.016335167212.49 schema:affiliation grid-institutes:grid.505613.4
206 schema:familyName Nakashima
207 schema:givenName M.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016335167212.49
209 rdf:type schema:Person
210 sg:person.0674453736.53 schema:affiliation grid-institutes:grid.410804.9
211 schema:familyName Okamoto
212 schema:givenName H.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674453736.53
214 rdf:type schema:Person
215 sg:person.0770416306.49 schema:affiliation grid-institutes:grid.416762.0
216 schema:familyName Kumada
217 schema:givenName T.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770416306.49
219 rdf:type schema:Person
220 grid-institutes:None schema:alternateName Department of Medicine, Aikawa Internal Hospital, Ibaraki, Japan, Japan
221 Department of Medicine, Kojima Internal Clinic, Gifu, Japan, Japan
222 schema:name Department of Medicine, Aikawa Internal Hospital, Ibaraki, Japan, Japan
223 Department of Medicine, Kojima Internal Clinic, Gifu, Japan, Japan
224 rdf:type schema:Organization
225 grid-institutes:grid.264706.1 schema:alternateName The Fourth Department of Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital, Kanagawa, Japan, Japan
226 schema:name The Fourth Department of Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital, Kanagawa, Japan, Japan
227 rdf:type schema:Organization
228 grid-institutes:grid.410804.9 schema:alternateName Immunology Division, Jichi Medical School, Tochigi, Japan, Japan
229 schema:name Immunology Division, Jichi Medical School, Tochigi, Japan, Japan
230 rdf:type schema:Organization
231 grid-institutes:grid.410849.0 schema:alternateName The Second Department of Medicine, Miyazaki Medical College, Miyazaki, Japan, Japan
232 schema:name The Second Department of Medicine, Miyazaki Medical College, Miyazaki, Japan, Japan
233 rdf:type schema:Organization
234 grid-institutes:grid.416762.0 schema:alternateName Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan, Japan
235 schema:name Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan, Japan
236 rdf:type schema:Organization
237 grid-institutes:grid.417136.6 schema:alternateName Department of Medicine, Tokyo National Chest Hospital, Tokyo, Japan, Japan
238 schema:name Department of Medicine, Tokyo National Chest Hospital, Tokyo, Japan, Japan
239 rdf:type schema:Organization
240 grid-institutes:grid.417200.0 schema:alternateName Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan, Japan
241 Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan, Japan
242 schema:name Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan, Japan
243 Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan, Japan
244 rdf:type schema:Organization
245 grid-institutes:grid.505613.4 schema:alternateName Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan
246 The Second Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan
247 schema:name Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan
248 The Second Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, Japan
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...